Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina

Corbo et al., Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Silico study of phytochemicals from 28 plants identifying hesperidin and quercetin as having the highest binding affinity for SARS-CoV-2 RdRp.
The highest affinity for Mpro was observed for genistein and hesperidin, with both compounds forming interactions of interest. Hesperidin and luteolin had the highest binding affinity for PLpro, but no significant interactions were observed. For RdRp, hesperidin and quercetin showed the highest binding affinity, with both forming interactions of interest. Hesperidin and fisetin had the highest binding affinity for spike glycoprotein, and both achieved significant interactions. The highest affinity for NendoU was obtained for hesperidin and isorhamnetin, with both compounds forming interactions of interest.
73 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Corbo et al., 3 Jun 2023, peer-reviewed, 6 authors. Contact: kasim.bajrovic@ingeb.unsa.ba.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina
Tarik Corbo, Abdurahim Kalajdzic, Dzenita Omerkic, Farah Catic, Naris Pojskic, Kasim Bajrovic
Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196
The outbreak of the coronavirus disease 2019, caused by the SARS-CoV-2 virus, has prompted global health concerns. In response, researchers have been conducting investigations on active compounds in plants that may hold the potential to inhibit the proliferation of the virus. The aim of this study was to simulate and predict structural interactions of selected compounds isolated from 28 endemic plants of Bosnia and Herzegovina against the main protease (Mpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), spike glycoprotein and uridylate-specific endoribonuclease (NendoU) of SARS-CoV-2. The majority of compounds, especially hesperidin, showed great binding affinity to the target proteins. The highest affinity for Mpro was observed for genistein and hesperidin, while in terms of structural interactions, both compounds achieved interactions of interest. Hesperidin and luteolin were the compounds with the highest binding affinity for PLpro, but no significant interactions were observed. For RdRp, hesperidin and quercetin showed the highest binding affinity, where both compounds formed interactions of interest. Hesperidin and fisetin were the compounds with the highest binding affinity for spike glycoprotein, and both compounds achieved significant interactions. The highest affinity for NendoU was obtained for hesperidin and isorhamnetin, where both compounds formed interactions of interest. Although these findings appear encouraging, further research is needed, which includes in vitro and in vivo assessments, along with clinical trials, to provide evidence for the potential therapeutic uses of these plants.
Authors' contributions Conceptualization and design: KB, TC; supervision: KB, NP; methods: AK, DZO, FC, TC; data collection and/or processing: AK, DZO, FC, TC; analysis and/or interpretation: AK, DZO, FC, TC; manuscript writing: AK, TC; critical review: KB, NP. All authors read and approved the final manuscript. Disclosure statement The authors report no conflict of interest.
References
Abdizadeh, Hadizadeh, Abdizadeh, In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2, Mol Divers
Adel, Elnaggar, Albohy, Evaluation of antiviral activity of carica papaya leaves against SARS-CoV-2 assisted by metabolomic profiling, RSC Adv
Adem, Eyupoglu, Ibrahim, Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (mpro) inhibitors to unveil a hope against COVID-19, Comput Biol Med
Agrawal, Agrawal, Blunden, Pharmacological significance of hesperidin and hesperetin, two citrus flavonoids, as promising antiviral compounds for prophylaxis against and combating COVID-19, Nat Prod Commun
Aini, Kharisma, Widyananda, Bioactive compounds from purslane (portulaca oleracea L.) and star anise (illicium verum hook) as SARS-CoV-2 antiviral agent via dual inhibitor mechanism: in silico approach, Pharmacogn J
Altu, Budiman, Razali, Technical data of In silico analysis of the interaction of dietary flavonoid compounds against spike-glycoprotein and proteases of SARS-CoV-2, Data
Amin, Banerjee, Ghosh, Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (mpro) and papain-like protease (PLpro) inhibitors, Bioorg Med Chem
Aranda, Wieczór, Terrazas, Mechanism of reaction of RNA-dependent RNA polymerase from SARS-CoV-2, Chem Catal
Bachar, Mazumder, Bachar, A review of medicinal plants with antiviral activity available in Bangladesh and mechanistic insight into their bioactive metabolites on SARS-CoV-2, HIV and HBV, Front Pharmacol
Basu, Sarkar, Maulik, Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2, Sci Rep
Begum, Srivastava, Ray, Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): in silico-molecular insight, Biochem Biophys Res Commun
Berman, Westbrook, Feng, The protein data bank, Nucleic Acids Res
Cai Y, Zhang, Xiao, Distinct conformational states of SARS-CoV-2 spike protein, Science
Chen, Tsai, Chang, The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, J Infect Public Health
Cho, Li, Lalonde, Drug repurposing for the SARS-CoV-2 papain-Like protease, ChemMedChem
Corbo, Miralem, Kalajdzic, In silico prediction of the inhibitory effect of phytochemical components extracted from knautia sarajevensis on the main protease of SARS-CoV-2 virus, GenApp
Das, Sarmah, Lyndem, An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study, J Biomol Struct Dyn
Farouk, Baig, Khan, Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: a viroinformatics study, Saudi J Biol Sci
Ferreira, Fadl, Villanueva, Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease, Front Chem
Frazier, Dillard, Krahn, Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U, Nucleic Acids Res
Gasmi, Mujawdiya, Lysiuk, quercetin in the prevention and treatment of coronavirus infections: a focus on SARS-CoV-2, Pharmaceuticals
Hm, Gareeb, Kaushik, Ginkgo biloba in the management of the COVID-19 severity, Arch Pharm (Weinheim)
Hognon, Marazzi, García-Iriepa, Atomistic-level description of the covalent inhibition of SARS-CoV-2 papain-like protease, IJMS
Hu, Guo, Zhou, Characteristics of SARS-CoV-2 and COVID-19, Nat Rev Microbiol
Ibrahim, Ismail, Bauer, Supporting SARS-CoV-2 papain-like protease drug discovery: in silico methods and benchmarking, Front Chem
Jendele, Krivak, Skoda, PrankWeb: a web server for ligand binding site prediction and visualization, Nucleic Acids Res
Jiang, Yang, Zhang, Potential inhibitors targeting papain-Like protease of SARS-CoV-2: two birds with one stone, Front Chem
Kaul, Paul, Kumar, Promising antiviral activities of natural flavonoids against SARS-CoV-2 targets: systematic review, IJMS
Kim Y, Wower, Maltseva, Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2, Commun Biol
Kim, Chen, Cheng, PubChem in 2021: new data content and improved web interfaces, Nucleic Acids Res
Kumar, Kashyap, Chowdhury, Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication, Phytomed
Kumar, Paul, A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle, Comput Biol Med
Laskowski, Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J Chem Inf Model
Lei, Kusov, Hilgenfeld, Nsp3 of coronaviruses: structures and functions of a large multi-domain protein, Antiviral Res
Li, Luan, Zhang, Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors, Biochem Biophys Res Commun
Liang, Pitsillou, Ververis, Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE monte carlo simulations, and in vitro activity inhibition, Chem Phys Lett
Liu, Zhang, Gao, Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis, Front Pharmacol
Ma, Wang, Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors, ACS Pharmacol Transl Sci
Matondo, Kilembe, Ngoyi, Oleanolic acid, ursolic acid and apigenin from ocimum basilicum as potential inhibitors of the SARS-CoV-2 main protease: a molecular docking study, IJPR
Mishra, Kaur, Singh, Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study, J Biomol Struct Dyn
Moradi, Golmohammadi, Najafi, In silico analysis of inhibiting papain-like protease from SARS-CoV-2 by using plant-derived peptides, Int J Pept Res Ther
Morris, Huey, Lindstrom, AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J Comput Chem
Mouffouk, Mouffouk, Mouffouk, Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2), Eur J Pharmacol
Munafò, Donati, Brindani, quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase, Sci Rep
O'boyle, Banck, James, Open babel: an open chemical toolbox, J Cheminform
Pandey, Rane, Chatterjee, Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development, J Biomol Struct Dyn
Pendyala, Patras, In silico screening of cyanobacterial and food bioactive compounds to predict potential inhibitors of COVID-19 main protease (mpro), papain-like protease (PLpro) and RNA-dependent RNA polymerase (RdRp). ChemRxiv. 2022. This content is a preprint and has not been peer-reviewed
Pettersen, Goddard, Huang, UCSF chimera-a visualization system for exploratory research and analysis, J Comput Chem
Ramesh, Kulkarni, Velusamy, Current update of phytotherapeutic agents in the treatment of COVID-19: in-silico based virtual screening approach for the development of antiviral drug, Front Biosci (Landmark Ed)
Rehman, Akhter, Batool, Effectiveness of natural antioxidants against SARS-CoV-2? Insights from the in-silico world, Antibiotics
Shahhamzehei, Abdelfatah, Efferth, In silico and in vitro identification of pan-coronaviral main protease inhibitors from a large natural product library, Pharmaceuticals
Singh, Sk, Sonawane, Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis, J Biomol Struct Dyn
Srinivasan, Brognaro, Prabhu, Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease, Commun Biol
Tejera, Pérez-Castillo Y, Toscano, Computational modeling predicts potential effects of the herbal infusion "horchata" against COVID-19, Food Chem
Trott, Olson, AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem
Ullrich, Nitsche, The SARS-CoV-2 main protease as drug target, Bioorg Med Chem Lett
Veeramachaneni, Thunuguntla, Bobbillapati, Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor, J Biomol Struct Dyn
Walls, Park Yj, Tortorici, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell
Wang, Zhu, Molecular docking for drug discovery and development: a widely used approach but far from perfect, Future Med Chem
Wu, Liu, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
{ 'indexed': {'date-parts': [[2023, 6, 10]], 'date-time': '2023-06-10T04:26:39Z', 'timestamp': 1686371199954}, 'reference-count': 61, 'publisher': 'Informa UK Limited', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 6, 3]], 'date-time': '2023-06-03T00:00:00Z', 'timestamp': 1685750400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ { 'name': 'Canton Sarajevo, Ministry for Science, Higher Education and Youth', 'award': ['27-02-11-4375-1/21']}], 'content-domain': {'domain': ['www.tandfonline.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 6, 3]]}, 'DOI': '10.1080/13102818.2023.2222196', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 8]], 'date-time': '2023-06-08T04:45:55Z', 'timestamp': 1686199555000}, 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: <i>in silico</i> evaluation ' 'of endemic plants of Bosnia and Herzegovina', 'prefix': '10.1080', 'volume': '37', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-4377-9793', 'authenticated-orcid': False, 'given': 'Tarik', 'family': 'Corbo', 'sequence': 'first', 'affiliation': [ { 'name': 'Laboratory for Bioinformatics and Biostatistics, Institute for ' 'Genetic Engineering and Biotechnology, University of Sarajevo, ' 'Sarajevo, Bosnia and Herzegovina'}]}, { 'ORCID': 'http://orcid.org/0000-0002-2824-2779', 'authenticated-orcid': False, 'given': 'Abdurahim', 'family': 'Kalajdzic', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory for Bioinformatics and Biostatistics, Institute for ' 'Genetic Engineering and Biotechnology, University of Sarajevo, ' 'Sarajevo, Bosnia and Herzegovina'}]}, { 'ORCID': 'http://orcid.org/0009-0008-1659-9122', 'authenticated-orcid': False, 'given': 'Dzenita', 'family': 'Omerkic', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Plant Production, Faculty of Agriculture and Food ' 'Science, University of Sarajevo, Sarajevo, Bosnia and ' 'Herzegovina'}]}, { 'ORCID': 'http://orcid.org/0009-0007-2415-0061', 'authenticated-orcid': False, 'given': 'Farah', 'family': 'Catic', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Biology, Faculty of Science, University of ' 'Sarajevo, Sarajevo, Bosnia and Herzegovina'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6765-2976', 'authenticated-orcid': False, 'given': 'Naris', 'family': 'Pojskic', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory for Bioinformatics and Biostatistics, Institute for ' 'Genetic Engineering and Biotechnology, University of Sarajevo, ' 'Sarajevo, Bosnia and Herzegovina'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7927-2417', 'authenticated-orcid': False, 'given': 'Kasim', 'family': 'Bajrovic', 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory for GMO and Food Biosafety, Institute for Genetic ' 'Engineering and Biotechnology, University of Sarajevo, Sarajevo, ' 'Bosnia and Herzegovina'}]}], 'member': '301', 'published-online': {'date-parts': [[2023, 6, 7]]}, 'reference': [ {'key': 'CIT0001', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11030-021-10230-6'}, {'key': 'CIT0002', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/D2RA04600H'}, { 'key': 'CIT0003', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.compbiomed.2022.105452'}, {'key': 'CIT0004', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1934578X211042540'}, {'key': 'CIT0005', 'doi-asserted-by': 'publisher', 'DOI': '10.5530/pj.2022.14.106'}, {'key': 'CIT0006', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ardp.202200188'}, {'key': 'CIT0007', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/data7110144'}, {'key': 'CIT0008', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bmc.2020.115860'}, {'key': 'CIT0009', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.checat.2022.03.019'}, {'key': 'CIT0010', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2021.732891'}, {'key': 'CIT0011', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-020-74715-4'}, {'key': 'CIT0012', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbrc.2021.07.050'}, {'key': 'CIT0013', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/28.1.235'}, {'key': 'CIT0014', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abd4251'}, {'key': 'CIT0015', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jiph.2022.11.022'}, {'key': 'CIT0016', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cmdc.202100455'}, {'key': 'CIT0017', 'doi-asserted-by': 'publisher', 'DOI': '10.31383/ga.vol6iss2ga03'}, { 'issue': '9', 'key': 'CIT0018', 'first-page': '3347', 'volume': '39', 'author': 'Das S', 'year': '2021', 'journal-title': 'J Biomol Struct Dyn'}, {'key': 'CIT0019', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.sjbs.2021.02.066'}, {'key': 'CIT0020', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2021.692168'}, {'key': 'CIT0021', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkab719'}, {'key': 'CIT0022', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ph15091049'}, {'key': 'CIT0023', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms23105855'}, {'key': 'CIT0024', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41579-020-00459-7'}, {'key': 'CIT0025', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2020.592289'}, {'key': 'CIT0026', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkz424'}, {'key': 'CIT0027', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2022.822785'}, {'key': 'CIT0028', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms222011069'}, {'key': 'CIT0029', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nar/gkaa971'}, {'key': 'CIT0030', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s42003-021-01735-9'}, {'key': 'CIT0031', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phymed.2020.153317'}, { 'key': 'CIT0032', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.compbiomed.2022.105231'}, {'key': 'CIT0033', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/ci200227u'}, {'key': 'CIT0034', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2017.11.001'}, {'key': 'CIT0035', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbrc.2020.11.083'}, {'key': 'CIT0036', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cplett.2021.139294'}, {'key': 'CIT0037', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2022.961154'}, {'key': 'CIT0038', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acsptsci.1c00240'}, { 'issue': '2', 'key': 'CIT0039', 'first-page': '1', 'volume': '6', 'author': 'Matondo A', 'year': '2021', 'journal-title': 'IJPR'}, {'key': 'CIT0040', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1868335'}, {'key': 'CIT0041', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10989-021-10331-8'}, {'key': 'CIT0042', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.21256'}, {'key': 'CIT0043', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejphar.2020.173759'}, {'key': 'CIT0044', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-022-14664-2'}, {'key': 'CIT0045', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1758-2946-3-33'}, {'key': 'CIT0046', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1796811'}, {'key': 'CIT0047', 'author': 'Pendyala B', 'year': '2022', 'journal-title': 'ChemRxiv'}, {'key': 'CIT0048', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.20084'}, {'key': 'CIT0049', 'doi-asserted-by': 'publisher', 'DOI': '10.31083/j.fbl2704123'}, { 'issue': '8', 'key': 'CIT0050', 'first-page': '1011', 'volume': '10', 'author': 'Rehman MFU', 'year': '2021', 'journal-title': 'Antibiotics (Basel, Switzerland)'}, {'key': 'CIT0051', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ph15030308'}, {'key': 'CIT0052', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1796810'}, {'key': 'CIT0053', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s42003-022-03737-7'}, {'key': 'CIT0054', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.foodchem.2021.130589'}, { 'key': 'CIT0055', 'volume-title': 'Version 2.5.4', 'author': 'The PyMOL Molecular Graphics System', 'year': '2022'}, { 'issue': '2', 'key': 'CIT0056', 'first-page': '455', 'volume': '31', 'author': 'Trott O', 'year': '2010', 'journal-title': 'J Comput Chem'}, {'key': 'CIT0057', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bmcl.2020.127377'}, {'key': 'CIT0058', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1773318'}, {'key': 'CIT0059', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.058'}, {'key': 'CIT0060', 'doi-asserted-by': 'publisher', 'DOI': '10.4155/fmc-2016-0143'}, {'key': 'CIT0061', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.apsb.2020.02.008'}], 'container-title': 'Biotechnology &amp; Biotechnological Equipment', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/13102818.2023.2222196', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 6, 10]], 'date-time': '2023-06-10T03:54:22Z', 'timestamp': 1686369262000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.tandfonline.com/doi/full/10.1080/13102818.2023.2222196'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 3]]}, 'references-count': 61, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 6, 3]]}}, 'alternative-id': ['10.1080/13102818.2023.2222196'], 'URL': 'http://dx.doi.org/10.1080/13102818.2023.2222196', 'relation': {}, 'ISSN': ['1310-2818', '1314-3530'], 'subject': ['Biotechnology'], 'container-title-short': 'Biotechnology &amp; Biotechnological Equipment', 'published': {'date-parts': [[2023, 6, 3]]}, 'assertion': [ { 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.', 'order': 1, 'name': 'peerreview_statement', 'label': 'Peer Review Statement'}, { 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tbeq20', 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tbeq20', 'order': 2, 'name': 'aims_and_scope_url', 'label': 'Aim & Scope'}, { 'value': '2023-03-02', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-05-29', 'order': 1, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-06-01', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-06-07', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit